CDK Cyclin-dependent kinase

Cat.No.	Name	Information
M1806	PD 0332991 HCL	PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc.
M1974	Roscovitine	Roscovitine (Seliciclib) is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5, with IC50 values of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
M2112	LY2835219 mesylate	LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively.
M1807	SCH727965 (dinaciclib)	SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively.
M3519	PHA-848125	PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7.
M5228	THZ1	THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.
M1710	Flavopiridol	Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively.
M6167	Palbociclib	Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases.
M5305	RO-3306	RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
M4889	Ribociclib succinate (LEE011 succinate)	Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
M25464	QR-6401	QR-6401 is a a highly potent and selective macrocyclic CDK2 inhibitor. QR-6401 demonstrated robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration.
M21223	DS96432529	DS96432529 is a potent bone anabolic agent with oral activity and CDK8 inhibitory activity.
M21214	AS-0141	AS-0141 (Cdc7-IN-6) is a potent Cdc7 kinase inhibitor (IC50=4 nM) with antitumor activity as described in WO2019165473A1, compound I-D. Cdc7 is a serine threonine protein kinase enzyme that is essential for the initiation of DNA replication during the cell cycle.
M21177	(-)-Enitociclib	(-)-Enitociclib ((-)-BAY-1251152) is an enantiomer of BAY-1251152 with a (-) spin. BAY-1251152 is a potent and highly selective inhibitor of cell cycle-dependent protein kinase (PTEF/CDK9).
M21041	MS140	MS140 is a specific and highly potent CDK4/6 kinase inhibitor and also a CDK4/6 degrader (PROTAC).
M21000	LY3405105	LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.
M20650	SEL120-34A	SEL120-34A is a novel inhibitor of Cyclin-dependent kinase 8 (CDK8) with IC50 values of 4.4 nM and 10.4 nM for CDK8/Cyclin C and CDK19/CyclinC respectively.
M20357	WAY-352563	WAY-352563 is a CDK9 inhibitor.
M20332	WAY-383487	WAY-383487 is a CDK9 inhibitor.
M20326	WAY-381332	WAY-381332 is a Mimetic CDK9 inhibitor.
M20323	WAY-643018	WAY-643018 is a CDK1, CDK2, and CDK4 inhibitor.
M20271	WAY-652641	WAY-652641 is a CDK inhibitor.
M20265	WAY-648936	WAY-648936 is a CDK1, CDK2, and CDK4 inhibitor.
M20262	WAY-647729	WAY-647729 is a CDK9 inhibitor.
M20258	WAY-642481	WAY-642481 is a CDK9 inhibitor.
M20243	WAY-635319	WAY-635319 is a CDK9 inhibitor.
M20234	WAY-632896	WAY-632896 is a Mimetic CDK9 inhibitor
M20205	WAY-612622	WAY-612622 is a CDK9 inhibitor.
M20187	WAY-601323	WAY-601323 is a Mimetic CDK9 inhibitor.
M20161	WAY-351812	WAY-351812 is a Novel CDK8 inhibitor.

By Signaling Pathways

By Product Type

Signaling Pathways

CDK Cyclin-dependent kinase

Get to Know Us

Customer Support

Resources

Contact Us